Big mergers and acquisitions activity may have waned across the medtech industry in the past year, but for the major medtech corporates, it’s business as usual, according to the leaders from Medtronic PLC, Johnson & Johnson and Olympus Medical Systems Group who gathered at the recent LSX World Congress in London to discuss commercial trends and the impact of the new European Medical Device Regulation (EU MDR) on innovation.
Rupert Winckler, Olympus’ head of new business development in Europe, Middle East and Africa (EMEA), said the general trends suggest that medtech M&A activity will remain constant in the long...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?